InfuSystem Approves $20M Stock Repurchase Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 18 2026
0mins
InfuSystem announced that the company's Board of Directors has approved a stock repurchase program authorizing the company to repurchase up to $20M of the company's outstanding common stock starting on July 1, 2026 and running through June 30, 2028. The program will supersede the previous authorization which is set to expire on June 30, 2026. Under the current authorization, the company repurchased approximately 1.6M shares of stock for approximately $11.9M though March 31, 2026. Repurchases will be made through open market purchases, private transactions, or otherwise in accordance with applicable federal securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934. Carrie Lachance, Chief Executive Officer of InfuSystem, said, "This authorization carries on the Company's established buyback policy which we have used when appropriate to enhance shareholder value. I believe the stock repurchase program demonstrates our confidence in being able to continue to execute with discipline, deliver profitable growth and drive long term value for the rest of 2026 and beyond. It also reflects the strength of our balance sheet and cash flows. Our top priority for use of capital remains making strategic investments that position the Company for sustainable growth, although this program provides us with the flexibility to be opportunistic in repurchasing shares when valuations become attractive."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INFU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INFU
Wall Street analysts forecast INFU stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.800
Low
12.00
Averages
13.67
High
15.00
Current: 8.800
Low
12.00
Averages
13.67
High
15.00
About INFU
InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
InfuSystem Approves $20 Million Stock Buyback Program
- Buyback Program Initiation: InfuSystem's board has approved a stock repurchase program allowing the company to buy back up to $20 million of its common stock from July 1, 2026, to June 30, 2028, reflecting confidence in future growth prospects.
- Positive Stock Reaction: Following the announcement, InfuSystem's shares rose over 4% in extended trading, indicating strong market confidence in the buyback program, which may further enhance investor sentiment.
- Historical Buyback Data: Under the current authorization, as of March 31, 2026, the company has repurchased approximately 1.6 million shares for about $11.9 million, demonstrating a consistent commitment to share repurchases and effective execution.
- Management Confidence: CEO Carrie Lachance emphasized that this buyback program not only continues the company's established repurchase policy but also showcases the company's ability to achieve profitable growth and long-term value creation, ensuring flexibility to repurchase shares when market conditions are favorable.
See More
InfuSystem Approves $20 Million Stock Repurchase Program
- Stock Repurchase Program: InfuSystem's Board of Directors has approved a stock repurchase program authorizing the company to buy back up to $20 million of its common stock from July 1, 2026, to June 30, 2028, reflecting the company's confidence in future growth.
- Previous Buyback Activity: As of March 31, 2026, InfuSystem repurchased approximately 1.6 million shares for about $11.9 million under the previous authorization, indicating a proactive approach to capital management.
- Flexible Capital Utilization: CEO Carrie Lachance emphasized that this repurchase program not only continues the company's established buyback policy but also provides flexibility to enhance shareholder value and support long-term growth when valuations are attractive.
- Business Model Overview: InfuSystem operates through two platforms, Patient Services and Device Solutions, covering oncology, pain management, and wound therapy, showcasing its comprehensive competitiveness in the medical equipment market.
See More
InfuSystem Holdings Reports Q1 2026 Earnings with Mixed Results
- Revenue Performance: InfuSystem reported Q1 2026 revenue of $33.7 million, a decline of $1 million from the prior year, although a 1.7% increase on a pro forma basis indicates resilience amid challenges.
- EBITDA Growth: Despite the revenue drop, adjusted EBITDA reached $6.4 million, remaining consistent with the previous year, while the EBITDA margin slightly improved to 18.9%, reflecting the company's cost control efforts.
- Wound Care Business Growth: Wound care net revenue was $2.1 million, more than doubling year-over-year with a 112% increase, driven by approximately 60% growth from the compression device product line, highlighting strong demand and market potential.
- ERP System Launch: The company successfully launched its new ERP system on March 1, 2026, facing initial challenges but expecting it to enhance operational efficiency and cost savings in the future, with management expressing optimism about cash flow stability.
See More
InfuSystem Q1 Results: Revenue Decline but Enhanced Profitability
- Revenue Overview: InfuSystem reported net revenues of $33.7 million for Q1, a 3% decline year-over-year primarily due to the restructuring of the GE Healthcare services contract; however, on a pro forma basis, net revenue grew by 1.7%, indicating improved profitability.
- Profitability Enhancement: Adjusted EBITDA stood at $6.4 million with an EBITDA margin of 18.9%, reflecting the company's successful strategy to reduce direct contract expenses, thereby enhancing overall economic performance despite lower revenues.
- Wound Care Growth: The wound care segment achieved net revenues of $2.1 million in Q1, more than doubling year-over-year, with approximately 60% of this growth driven by sales of compression devices, showcasing the potential of new therapies and expanding market share.
- ERP System Launch: The company successfully went live with its new ERP system on March 1, 2026, which is expected to improve productivity and cost visibility, optimize the utilization of medical devices, and provide a scalable platform for future growth.
See More
InfuSystem to Release Q1 2026 Financial Results on May 7, 2026
- Earnings Release Schedule: InfuSystem Holdings, Inc. will issue its Q1 2026 financial results on May 7, 2026, before market open, reflecting the company's ongoing commitment to transparency and investor communication.
- Investor Conference Call: The company will hold a conference call at 9:00 a.m. Eastern Time on the same day to discuss its financial results, enhancing engagement with investors and stakeholders.
- Participation Details: Investors can join the call by dialing (833) 366-1127 or (412) 902-6773, or by listening via a live webcast on the company's website, demonstrating the company's emphasis on accessible communication channels.
- Replay Information: A replay of the call will be available until May 14, 2026, allowing investors who cannot participate live to access key information, thereby ensuring comprehensive communication of financial performance.
See More
InfuSystem Holdings Reports Strong Q4 2025 Earnings with Strategic Growth Outlook
- Significant Revenue Growth: InfuSystem reported net revenue of $36.2 million for Q4 2025, reflecting a 7% year-over-year increase, with Oncology and Wound Care segments growing by 2.8% and over 160% respectively, indicating strong performance in the medical device market.
- Record Adjusted EBITDA: The adjusted EBITDA for Q4 reached $8.8 million, representing 24.3% of net revenue, marking a quarterly record that highlights the company's success in cost control and operational efficiency.
- Optimistic Future Outlook: Management anticipates revenue growth between 6% and 8% for 2026, despite a $7.1 million revenue reduction due to contract restructuring, with new products and technology-driven efficiencies expected to support this growth.
- Robust Cash Flow: Operating cash flow for 2025 exceeded $24.4 million, with available liquidity nearing $58 million at year-end, demonstrating the company's ongoing commitment to capital allocation and shareholder value creation.
See More
InfuSystem Approves $20 Million Stock Buyback Program
- Buyback Program Initiation: InfuSystem's board has approved a stock repurchase program allowing the company to buy back up to $20 million of its common stock from July 1, 2026, to June 30, 2028, reflecting confidence in future growth prospects.
- Positive Stock Reaction: Following the announcement, InfuSystem's shares rose over 4% in extended trading, indicating strong market confidence in the buyback program, which may further enhance investor sentiment.
- Historical Buyback Data: Under the current authorization, as of March 31, 2026, the company has repurchased approximately 1.6 million shares for about $11.9 million, demonstrating a consistent commitment to share repurchases and effective execution.
- Management Confidence: CEO Carrie Lachance emphasized that this buyback program not only continues the company's established repurchase policy but also showcases the company's ability to achieve profitable growth and long-term value creation, ensuring flexibility to repurchase shares when market conditions are favorable.
See More
InfuSystem Approves $20 Million Stock Repurchase Program
- Stock Repurchase Program: InfuSystem's Board of Directors has approved a stock repurchase program authorizing the company to buy back up to $20 million of its common stock from July 1, 2026, to June 30, 2028, reflecting the company's confidence in future growth.
- Previous Buyback Activity: As of March 31, 2026, InfuSystem repurchased approximately 1.6 million shares for about $11.9 million under the previous authorization, indicating a proactive approach to capital management.
- Flexible Capital Utilization: CEO Carrie Lachance emphasized that this repurchase program not only continues the company's established buyback policy but also provides flexibility to enhance shareholder value and support long-term growth when valuations are attractive.
- Business Model Overview: InfuSystem operates through two platforms, Patient Services and Device Solutions, covering oncology, pain management, and wound therapy, showcasing its comprehensive competitiveness in the medical equipment market.
See More
InfuSystem Holdings Reports Q1 2026 Earnings with Mixed Results
- Revenue Performance: InfuSystem reported Q1 2026 revenue of $33.7 million, a decline of $1 million from the prior year, although a 1.7% increase on a pro forma basis indicates resilience amid challenges.
- EBITDA Growth: Despite the revenue drop, adjusted EBITDA reached $6.4 million, remaining consistent with the previous year, while the EBITDA margin slightly improved to 18.9%, reflecting the company's cost control efforts.
- Wound Care Business Growth: Wound care net revenue was $2.1 million, more than doubling year-over-year with a 112% increase, driven by approximately 60% growth from the compression device product line, highlighting strong demand and market potential.
- ERP System Launch: The company successfully launched its new ERP system on March 1, 2026, facing initial challenges but expecting it to enhance operational efficiency and cost savings in the future, with management expressing optimism about cash flow stability.
See More
InfuSystem Q1 Results: Revenue Decline but Enhanced Profitability
- Revenue Overview: InfuSystem reported net revenues of $33.7 million for Q1, a 3% decline year-over-year primarily due to the restructuring of the GE Healthcare services contract; however, on a pro forma basis, net revenue grew by 1.7%, indicating improved profitability.
- Profitability Enhancement: Adjusted EBITDA stood at $6.4 million with an EBITDA margin of 18.9%, reflecting the company's successful strategy to reduce direct contract expenses, thereby enhancing overall economic performance despite lower revenues.
- Wound Care Growth: The wound care segment achieved net revenues of $2.1 million in Q1, more than doubling year-over-year, with approximately 60% of this growth driven by sales of compression devices, showcasing the potential of new therapies and expanding market share.
- ERP System Launch: The company successfully went live with its new ERP system on March 1, 2026, which is expected to improve productivity and cost visibility, optimize the utilization of medical devices, and provide a scalable platform for future growth.
See More
InfuSystem to Release Q1 2026 Financial Results on May 7, 2026
- Earnings Release Schedule: InfuSystem Holdings, Inc. will issue its Q1 2026 financial results on May 7, 2026, before market open, reflecting the company's ongoing commitment to transparency and investor communication.
- Investor Conference Call: The company will hold a conference call at 9:00 a.m. Eastern Time on the same day to discuss its financial results, enhancing engagement with investors and stakeholders.
- Participation Details: Investors can join the call by dialing (833) 366-1127 or (412) 902-6773, or by listening via a live webcast on the company's website, demonstrating the company's emphasis on accessible communication channels.
- Replay Information: A replay of the call will be available until May 14, 2026, allowing investors who cannot participate live to access key information, thereby ensuring comprehensive communication of financial performance.
See More
InfuSystem Holdings Reports Strong Q4 2025 Earnings with Strategic Growth Outlook
- Significant Revenue Growth: InfuSystem reported net revenue of $36.2 million for Q4 2025, reflecting a 7% year-over-year increase, with Oncology and Wound Care segments growing by 2.8% and over 160% respectively, indicating strong performance in the medical device market.
- Record Adjusted EBITDA: The adjusted EBITDA for Q4 reached $8.8 million, representing 24.3% of net revenue, marking a quarterly record that highlights the company's success in cost control and operational efficiency.
- Optimistic Future Outlook: Management anticipates revenue growth between 6% and 8% for 2026, despite a $7.1 million revenue reduction due to contract restructuring, with new products and technology-driven efficiencies expected to support this growth.
- Robust Cash Flow: Operating cash flow for 2025 exceeded $24.4 million, with available liquidity nearing $58 million at year-end, demonstrating the company's ongoing commitment to capital allocation and shareholder value creation.
See More
